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Summary
Under fasting conditions, the cAMP-responsive CREB coactivator TORC2 promotes glucose homeostasis by stimulating
the gluconeogenic program in liver. Following its nuclear translocation in response to elevations in circulating glucagon,
TORC2 regulates hepatic gene expression via an association with CREB on relevant promoters. Here, we show that, in
parallel with their effects on glucose output, CREB and TORC2 also enhance insulin signaling in liver by stimulating
expression of the insulin receptor substrate 2 (IRS2) gene. The induction of hepatic IRS2 during fasting appears critical
for glucose homeostasis; knockdown of hepatic IRS2 expression leads to glucose intolerance, whereas hepatic IRS2
overexpression attenuates the gluconeogenic program and reduces fasting glucose levels. By stimulating the expression
of IRS2 in conjunction with gluconeogenic genes, the CREB:TORC2 pathway thus triggers a feedback response that limits
glucose output from the liver during fasting.Introduction
Fasting and caloric restriction (CR) have been shown to extend
lifespan and to improve energy balance in a wide variety of
organisms. CR enhances glucose homeostasis in part by im-
proving insulin sensitivity, although the underlying mechanism
is unclear (Bartke and Brown-Borg, 2004; Escalante-Pulido et
al., 2003; Heilbronn and Ravussin, 2003).
Under fasting conditions, elevations in pancreatic glucagon
trigger the expression of the gluconeogenic program via the
cAMP-responsive factor CREB (Mayr and Montminy, 2001;
Shaywitz and Greenberg, 1999). Mice deficient in hepatic CREB
activity, either via targeted disruption of the CREB gene or by
expression of a dominant-negative CREB polypeptide called
A-CREB (Ahn et al., 1998), display fasting hypoglycemia and
reduced expression of gluconeogenic genes (Herzig et al.,
2001).
In a recent study, we found that glucagon stimulates CREB
activity via induction of the coactivator TORC2 (Conkright et
al., 2003a; Iourgenko et al., 2003; Koo et al., 2005; Screaton et
al., 2004). Sequestered in the cytoplasm via a phosphorylation-
dependent interaction with 14-3-3 proteins in the fed state,
TORC2 is rapidly dephosphorylated and translocated to the
nucleus in response to fasting signals, where it stimulates the
gluconeogenic program via a direct interaction with CREB.
Knockdown of hepatic TORC2 profoundly reduces glucose
output and gluconeogenic gene expression in mice (Koo et al.,
2005). Indeed, TORC2 overexpression strongly induces glu-
cose output in primary hepatocytes exposed to cAMP agonist.
But TORC2 has more modest effects on circulating glucose
levels when expressed at similar levels in liver in vivo, suggest-CELL METABOLISM : NOVEMBER 2005 · VOL. 2 · COPYRIGHT © 2005 Eing the presence of counter-regulatory controls that feed back
on this pathway and protect against fasting hyperglycemia.
Previous studies showing that the cAMP pathway promotes
insulin signaling in pancreatic islets by stimulating expression
of insulin receptor substrate 2 (IRS2) gene (Jhala et al., 2003)
prompted us to examine whether TORC2 limits glucose output
from the liver by regulating hepatic IRS2 expression in parallel
with the gluconeogenic program during fasting. We found that
cAMP triggers IRS2 expression and enhances insulin signaling
in hepatocytes via a CREB/TORC2-dependent mechanism. In-
deed, acute disruption of hepatic IRS2 expression led to fast-
ing hyperglycemia as well as elevated expression of the gluco-
neogenic program. The induction of IRS2 by TORC2 thus limits
glucose output from the liver and may explain the well-recog-
nized effects of acute caloric restriction in enhancing insulin
sensitivity.
Results
The importance of IRS2 in regulating glucose output from liver
(Kido et al., 2000; Kubota et al., 2000; Withers et al., 1998)
prompted us to examine the dynamics of IRS2 expression rela-
tive to the feeding/fasting transition. Levels of hepatic IRS2
mRNA and protein increased robustly during fasting, declining
to near undetectable levels during ad libitum feeding or refeed-
ing conditions (Figure 1A). By contrast, levels of IRS1 and insu-
lin receptor appeared relatively constant throughout, suggest-
ing that fasting signals specifically induce IRS2 expression.
We evaluated the importance of IRS2 induction during fast-
ing for glucose homeostasis by acute knockdown of hepatic
IRS2 expression with an adenovirus IRS2 RNAi construct (Ad-LSEVIER INC. DOI 10.1016/j.cmet.2005.09.008 331
S H O R T A R T I C L EFigure 1. Induction of IRS2 in liver during fasting is required for glucose homeostasis
A) Top, Western blot analysis of hepatic IRS2 protein levels under ad libitum feeding, fasted, and refed conditions. Levels of insulin receptor (IR) and IRS1 shown for
comparison. Bottom, PCR analysis of hepatic IRS2 mRNA levels under ad libitum feeding, fasted, and refed conditions.
B) Effect of acute hepatic IRS2 knockdown on fasting glucose metabolism. Top-left, circulating glucose levels in mice (n = 5) infected for 4 days with unspecific (Ad-
USi) or IRS2 siRNA-expressing adenovirus. Top-right, glucose tolerance test of Ad-USi and Ad-IRS2i mice (n = 5). Following intraperitoneal injection with glucose (2g/kg),
glucose levels were monitored at time points indicated. Bottom, Western blot analysis of IRS1 and IRS2 proteins in livers from mice infected with unspecific control
(US), Ad-IRS1i, or Ad-IRS2i RNAi adenoviruses.
C) PCR analysis of gluconeogenic gene (PEPCK, G6P, PGC-1α) expression in livers of control Ad-USi and Ad-IRS2i-expressing mice collected under fasted conditions.
L32 mRNA levels shown as control.
D) Effect of hepatic Ad-IRS1i and Ad-IRS2i mediated knockdown, alone or in combination, on fasting glucose levels relative to control Ad-USi mice (n = 4).
Data in (B) and (D) are represented as mean ± standard deviation.IRS2i) (Figure 1B). Compared with control littermates, Ad-IRS2i
mice exhibited higher fasting blood glucose levels as well as
marked glucose intolerance in response to intraperitoneal glu-
cose administration (Figure 1B). Indeed, gluconeogenic gene
expression (PEPCK, G6P, PGC-1α) during fasting was in-
creased in IRS2 knockdown relative to control littermates (Fig-
ure 1C).
To determine the relative contributions of hepatic IRS1 and
IRS2 in this regard, we prepared an Ad- IRS1 RNAi construct
(Figure 1B). By contrast with Ad-IRS2i, Ad-IRS1i mice showed
no change in fasting glucose levels relative to control litter-
mates (Figure 1D). Nevertheless, mice expressing both Ad-
IRS1i andAd-IRS2i showed higher fasting glucose levels com-
pared with Ad-IRS2i mice, indicating that IRS1 is capable of
compensating to some extent for the loss of IRS2 signaling
(Figure 1D).
Hepatic IRS2 expression is often reduced in mouse models
of Type II diabetes, reflecting in part the inhibitory effects of
hyperinsulinemia on expression of the IRS2 gene (Brady, 2004;
White, 2003). Correspondingly, levels of hepatic IRS2 protein
were dramatically lower in db/db diabetic relative to control332mice, whereas amounts of IRS1 remained comparable be-
tween the two groups (Figure 2A). To test whether restoring
IRS2 expression is sufficient to promote normoglycemia in a
diabetic animal model, we injected db/db mice with Ad-IRS2.
Relative to control Ad-GFP littermates, Ad-IRS2 mice showed
a progressive decline in circulating glucose concentrations dur-
ing fasting, reaching near normal levels (100 mg/dl) 8 days
postinfection (Figure 2B). Ad-IRS2 also enhanced insulin sensi-
tivity in db/db mice, as determined by intraperitoneal glucose
tolerance test; and levels of circulating insulin were corre-
spondingly reduced by nearly 70% in IRS2 compared to con-
trol littermates (Figure 2B, bottom panel; Figure 2C). Similar
effects of Ad-IRS2 on glucose tolerance were also obtained
with wild-type mice (not shown).
Insulin regulates hepatic metabolism by stimulating a cas-
cade of lipid kinases that culminate in the phosphorylation and
activation of the Ser/Thr kinase Akt/PKB (Brazil and Hem-
mings, 2001). We tested whether hepatic Ad-IRS2 expression
was sufficient to potentiate Akt activation and to enhance Ser9
phosphorylation of GSK3, a downstream target of Akt. Com-
pared with control Ad-GFP littermates, liver extracts from Ad-CELL METABOLISM : NOVEMBER 2005
Role of TORC2 in insulin signalingFigure 2. Hepatic IRS2 promotes glucose homeostasis by reducing expression of the gluconeogenic program in liver during fasting
A) Western blot assay of liver extracts from fasted wild-type and db/db diabetic mice showing levels of CREB, IRS1, and IRS2. Right, Western blot assay of fasting
hepatic IRS2 levels in db/db mice infected with Ad-GFP or Ad-IRS2 relative to wild-type Ad-GFP infected mice.
B) Top, fasting glucose levels in db/db mice infected with Ad-GFP or Ad-IRS2 adenovirus. Days after infection are indicated. Stippled line indicates normal fasting
glucose levels. Bottom, circulating insulin levels in Ad-GFP and Ad-IRS2 db/db mice collected under fasting conditions. Plasma insulin levels were determined 8 days
postinfection (n = 5).
C) Glucose tolerance test of db/db mice infected with Ad-GFP or Ad-IRS2 adenovirus (n = 5). Plasma glucose levels were determined at time points indicated (in min)
after IP injection of glucose (2 g/kg).
D) Effect of IRS2 expression on insulin signaling in livers of db/db diabetic mice. Levels of total and phospho (Ser473) Akt as well as amounts of total and phospho
(Ser9)GSK3β are shown for four different mice.
E) Effect of Ad-IRS2 infection on gluconeogenic gene expression in fasted db/db mice. Q-PCR analysis of hepatic PEPCK and G6Pase mRNA levels after normalizing
to L32 gene expression in Ad-GFP and Ad-IRS2 db/db mice (n = 4).
Data in (B), (C), and (E) are represented as mean ± standard deviation.IRS2 mice contained far higher amounts of phospho (Ser473)
Akt and phospho (Ser9) GSK3 by Western blot assay (Figure
2D). In keeping with these effects, gluconeogenic gene expres-
sion was markedly reduced in IRS2 expressing db/db mice,
demonstrating that IRS2 promotes glucose homeostasis, in
part by disrupting expression of the gluconeogenic program
(Figure 2E).
The ability of fasting signals to stimulate IRS2 expression led
us to examine the role of CREB in this process. The mouse
IRS2 promoter contains a consensus CRE at –671 (Jhala etCELL METABOLISM : NOVEMBER 2005al., 2003). In gel mobility shift assays, a double-stranded oligo
containing the IRS2 CRE was found to bind CREB family mem-
bers CREB-1 and CREM (data not shown, Figure 3A). Binding
of CREM to the IRS2 CRE sequence was readily disrupted by
adding 50-fold molar excess unlabeled wild-type but not mu-
tant CRE oligonucleotide, demonstrating that the binding of
CREB family members to this site is indeed specific.
Consistent with CRE binding studies, exposure of HepG2
hepatocytes to FSK stimulated a wild-type IRS2 luciferase re-
porter 7-fold but had no effect on mutant IRS2 reporter con-333
S H O R T A R T I C L EFigure 3. Fasting signals promote hepatic IRS2 expression via the cAMP-responsive factor CREB
A) Gel mobility shift assay of 32p-labeled CRE oligonucleotide from the IRS-2 promoter. Incubation of recombinant CREM with 50-fold molar excess unlabeled wild-
type (WT) and mutant (CRE) CRE oligonucleotide competitors shown.
B) Transient assays of mouse hepatocytes transfected with IRS2-luciferase reporter constructs. Effect of FSK on activity of wild-type and CRE mutant IRS2 promoter
constructs.
C) Effect of CREB dominant-negative polypeptide (A-CREB) on IRS-2 reporter activity in cells transfected with PKA expression vector. Luciferase activity was normalized
to cotransfected RSV-β galactosidase activity.
D) Top, chromatin immunoprecipitation (ChIP) assay showing recovery of PCR-amplified IRS2 promoter fragment from immunoprecipitates of CREB prepared from
mouse hepatocytes. Absence of control ACTB (CON) promoter fragment in CREB immunoprecipitates shown to confirm specificity of the CREB antiserum. Bottom,
PCR analysis of hepatic IRS2 mRNA levels in CREB+/− mice compared to control littermates under fasted conditions. mRNA levels for the constitutively expressed L32
gene are also shown.
E) Effect of cAMP/CREB pathway in promoting insulin signaling in hepatocytes. Top, primary cultures of rat hepatocytes were infected with dominant-negative A-CREB
or control GFP adenovirus for 48 hr and then exposed to FSK or DMSO vehicle for 8 hr. Effect of subsequent short-term (30 min) insulin treatment on Ser473
phosphorylation of Akt under various conditions shown by Western blot assay. Levels of total Akt and IRS2 protein also indicated.
F) Western blot showing effect of Ad-CREB RNAi or unspecific (USi) RNAi adenovirus (3 day infection) on IRS2 levels in primary rat hepatocytes. Effect of insulin
treatment (30 min.) on AKT Ser473 phosphorylation indicated. Prior treatment with FSK (4 hr) shown.
Data in (B) and (C) are represented as mean ± standard deviation.taining substitutions within the CRE that block CREB binding
(Figure 3B). Indeed, overexpression of the catalytic subunit for
the cAMP-dependent protein kinase A (PKA) enhanced IRS2
promoter activity 10-fold; and these effects were disrupted by
expression of a dominant-negative polypeptide A-CREB (Ahn
et al., 1998), which blocks the DNA binding activity of CREB
family members (CREB-1, CREM, ATF-1) but not other bZIP
transcription factors (Figure 3C).
In chromatin immunoprecipitation (ChIP) assays of mouse
hepatocytes, the IRS2 promoter was efficiently recovered from
CREB immunoprecipitates whereas a control (ACTB) promoter
lacking a consensus CRE site was not (Figure 3D, top). Indeed,
hepatic IRS2 mRNA levels were reduced in fasted CREB+/−
knockout mice compared to wild-type littermates (Figure 3D,334bottom). Taken together, these experiments reveal that the
IRS2 gene is indeed a direct target of CREB action in hepato-
cytes.
Having seen that fasting signals trigger expression of the
IRS2 gene via a CREB-dependent mechanism, we examined
whether these effects are propagated at the level of IRS2 pro-
tein accumulation. Exposure of primary rat hepatocytes to
FSK-induced IRS2 protein levels gradually over a 6–12 hr
period; and the accumulation of IRS2 protein was completely
suppressed either by blocking cellular CREB activity with Ad-
A-CREB (Figure 3E) or by reducing endogenous CREB expres-
sion with Ad-CREB RNAi (Figure 3F).
The ability of CREB to promote IRS2 mRNA and protein ac-
cumulation in response to cAMP agonist led us to considerCELL METABOLISM : NOVEMBER 2005
Role of TORC2 in insulin signalingFigure 4. The CREB coactivator TORC2 promotes hepatic IRS2 expression and enhances insulin signaling in vivo
A) Effect of Adenoviral TORC2 relative to control GFP adenovirus on IRS2 mRNA levels in primary rat hepatocytes. Glucose 6 phosphatase mRNA levels shown for
comparison. Treatment with FSK indicated.
B) Left, Western blot assays showing effect of Ad-TORC2 expression in primary hepatocytes on IRS2 protein levels and on insulin-dependent phosphorylation of Akt
at Ser473. IRS1 and TORC2 levels are also shown. Treatment with insulin (30 min) indicated. Right, bar graph showing relative levels of phospho (Ser473) Akt in Ad-
GFP or Ad-TORC2 hepatocytes exposed to insulin (30 min), as measured by densitometric analysis.
C) Effect of intraperitoneal insulin treatment (10 min.) on hepatic Ser473 phosphorylation of Akt in Ad-USi and Ad-TORC2i mice. Western blot assay of liver extracts
showing amounts of IRS2 and Phospho (Ser473) Akt in both groups. Treatment with insulin is indicated. Bottom, levels of TORC2 protein in Ad-USi and Ad-TORC2i
livers. Right, relative levels of phospho (Ser473)Akt in liver extracts from Ad-USi and Ad-TORC2i mice, measured by densitometric analysis.
D) Model for TORC2 action in liver. Under fasting conditions, TORC2 stimulates hepatic glucose output via induction of gluconeogenic genes in response to pancreatic
glucagon. In parallel, TORC2 protects against hyperglycemia by stimulating expression of IRS2 and thereby enhancing insulin signaling.
Data in (A) and (C) are represented as mean ± standard deviation.whether this pathway enhances insulin signaling and potenti-
ates activation of downstream effectors like Akt/PKB. Consis-
tent with its effects on IRS2 accumulation, FSK pretreatment
(8 hr) increased Ser473 phosphorylation of Akt in response to
short-term exposure (30 min) to insulin (Figure 3E). Conversely,
hepatocytes deficient in CREB activity due either to Ad-A-
CREB expression (Figure 3E) or to knockdown of CREB with
Ad-CREB RNAi construct (Figure 3F) were far less responsive
to insulin treatment.
Having seen that CREB promotes insulin signaling by stimu-
lating IRS2 expression, we sought to determine the mechanism
underlying these effects. The importance of the CREB coacti-
vator TORC2 for induction of the gluconeogenic program dur-
ing fasting (Koo et al., 2005) prompted us to evaluate its role
in IRS2 activation. Following exposure to FSK, Ad-TORC2 in-
creased amounts of IRS2 mRNA to a similar extent (10-fold) asCELL METABOLISM : NOVEMBER 2005the gluconeogenic Glucose 6 Phosphatase (G6Pase) gene in
primary hepatocytes (Figure 4A). Correspondingly, Ad-TORC2
also enhanced accumulation of IRS2 protein but had no effect
on IRS1 levels. Indeed, Ad-TORC2 expressing hepatocytes
were 2- to 3-fold more responsive to acute insulin stimulation,
as determined by Akt phosphorylation (Figure 4B).
To determine whether TORC2 is required for IRS2 expression
and insulin signaling in liver, we injected mice with an adenovi-
rus TORC2 RNAi construct (Ad-TORC2 RNAi). Compared with
control mice injected with an unspecific RNAi adenovirus (Ad-
USi), Ad-TORC2 RNAi mice exhibited markedly lower TORC2
protein levels by Western blot assay (Figure 4C, bottom). Cor-
respondingly, IRS2 protein was almost undetectable in liver ex-
tracts from Ad-TORC2 RNAi mice, confirming the importance
of this coactivator in mediating induction of the IRS2 gene dur-
ing fasting (Figure 4C, top). Ad-TORC2 RNAi mice were also335
S H O R T A R T I C L Eless responsive to insulin; following intraperitoneal injection of
insulin (10 min), the accumulation of phospho (Ser473) Akt in
Ad-TORC2 RNAi mice was reduced 2-fold compared to control
mice (Figure 4C). Taken together, these results suggest that
the coordinate induction of IRS2 and gluconeogenic genes by
TORC2 provides important feedback controls that ensure
against fasting hyperglycemia due to excessive hepatic glu-
cose output (Figure 4D).
Discussion
TORC2 has been shown to promote hepatic glucose output
during fasting by stimulating expression of the gluconeogenic
program in response to glucagon (Koo et al., 2005). By contrast
with its robust activity in primary hepatocytes, TORC2 has
more modest effects on gluconeogenesis when expressed in
liver. We found that fasting signals also enhance IRS2 gene
expression via the CREB:TORC2 pathway. The induction of
IRS2 potentiates insulin signaling in primary hepatocytes, as
revealed by enhanced phosphorylation of Akt in response to
acute insulin stimulation. Conversely, knockdown of hepatic
IRS2 expression led to fasting hyperglycemia with elevated ex-
pression of gluconeogenic genes, pointing to an important role
for IRS2 in limiting glucose output in the fasted state.
TORC2 and CREB are likely to regulate IRS2 expression in
concert with other transcriptional regulators, most notably the
forkhead protein FOXO1 (Ide et al., 2004). Indeed, forkhead
proteins have also been found to exert priming effects on insu-
lin signaling; Tjian and colleagues found that Drosophila FOXO
(dFOXO) strongly induced expression of the insulin receptor
(IR) gene by binding to conserved FOXO responsive elements
in the dIR promoter (Puig et al., 2003). Thus, in addition to
constraining glucose output, fasting signals may prepare cer-
tain tissues for the transition to feeding by upregulating com-
ponents of the insulin signaling pathway.
By contrast with IRS2, hepatic IRS1 expression did not differ
between fasting and feeding periods; and acute knockdown of
IRS1 had little effect on fasting glucose levels. These results
are consistent with previous gene disruption studies showing
that IRS1 promotes insulin signaling primarily in skeletal mus-
cle (Araki et al., 1994; Tamemoto et al., 1994). Our results differ
from those reported by Kahn and colleagues, who recently ob-
served greater effects of IRS-1 relative to IRS-2 on gluco-
neogenic gene expression in their knockdown experiments
(Taniguchi et al., 2005). The reasons for this discrepancy are
unclear but may reflect differences in knockdown efficiency.
The notion that IRS2 performs a critical role in liver glucose
metabolism during fasting is further supported by Ad-IRS2
overexpression experiments in db/db diabetic mice, which ex-
hibit low levels of hepatic IRS2 but not IRS1. The loss of IRS2
expression during feeding and in db/db mice is likely to reflect
combined effects of hyperinsulinema on IRS2 protein recycling
and degradation as well as on transcriptional regulation by
Foxo family members (Rui et al., 2002; Shi et al., 2004). Indeed,
modest overexpression of IRS2 was sufficient to reduce fasting
glucose levels and gluconeogenic gene expression to near nor-
mal levels in db/db mice.
Exercise and short-term caloric restriction have been shown
to improve insulin sensitivity in peripheral tissues (Bartke and
Brown-Borg, 2004; Escalante-Pulido et al., 2003; Heilbronn
and Ravussin, 2003). Based on its ability to potentiate insulin336signaling, TORC2 may contribute to the salutary effects of CR
on glucose homeostasis in liver and perhaps other tissues. Fu-
ture studies in lower organisms like Drosophila may reveal
whether TORC2 also mediates certain effects of CR on lon-
gevity.
Experimental procedures
Plasmids
The pXp2 IRS-2 luciferase reporter vector, the expression vectors for PKAc,
and A-CREB were described previously (Herzig et al., 2003, 2001). To gen-
erate pU6-IRS2 RNAi and pU6-IRS1 RNAi constructs, palindromic se-
quences corresponding to nucleotides 258–280 from mouse IRS2 coding
sequence (5#-GGGCGCGCCGAAGCGAGTGATC-3#) and nucleotides 936–
957 from mouse IRS1 coding sequence (5#−GGGTGGGAAACCAGGTTC
CTTC-3#) were linked to human U6 promoter in the pBluescript KS vector.
The unspecific control was described elsewhere (Koo et al., 2004). To gen-
erate FLAG IRS2, the coding sequence of mouse IRS2 was PCR amplified
from the His IRS2 vector (kindly provided by Morris White) and subcloned
into FLAG pCDNA3 (Conkright et al., 2003b).
Culture of primary hepatocytes
Rat primary hepatocytes were prepared from 200–300 g of Sprague-Dawley
rats by collagenase perfusion method as described previously (Koo et al.,
2004). 1 × 106 cells were plated in 6-well plates with medium 199 (Invitro-
gen, Carlsbad, California) supplemented by 10% FBS, 10 units/ml penicillin,
10 g/ml streptomycin, and 10 nM dexamethasone for 3–6 hr. After attach-
ment, cells were infected with adenoviruses expressing either GFP or
A-CREB, TORC2, or CREB RNAi, for 16 hr. Subsequently, cells were main-
tained in medium 199 without FBS and dexamethasone for 8 hr, treated
with 10 M forskolin or DMSO for 8 hr, and then with 100 nM insulin for
30 min.
Transfection assays
Human hepatoma HepG2 cells were maintained with Ham’s F12 medium
supplemented with 10% FBS (Invitrogen, Carlsbad, California). For trans-
fection, Fugene 6 reagent (Promega, Madison, Wisconsin) was used ac-
cording to the manufacturer’s instructions. Each transfection was per-
formed with 50 ng of luciferase construct, 25 ng of β galactosidase
expression plasmid, and 25 ng each of expression vector for PKAc and
A-CREB. Luciferase activity was normalized to β galactosidase activity
(Jhala et al., 2003).
Recombinant adenoviruses
Adenoviruses expressing GFP only, A-CREB, and unspecific control were
described previously (Herzig et al., 2001; Koo et al., 2004). Adenoviruses
were generated by homologous recombination between adenovirus back-
bone vector pAD-Easy and linearized transfer vector pAD-Track that con-
tains U6-IRS1 RNAi, U6-IRS2 RNAi, and CMV-FLAG IRS2 cDNA, respec-
tively. For animal experiments, viruses were purified on a CsCl gradient and
then dialyzed against PBS buffer containing 10% glycerol, prior to injection.
Animal experiments
Male 7-week-old C57BL6 mice and db/db mice were purchased from the
Jackson Laboratory and maintained on regular chow under a 12 hr light-
dark cycle. 0.5 × 109 plaque-forming units per recombinant adenovirus
were delivered by systemic tail vein injection to mice that were anaesthe-
tized with Iso-Flurane. For measuring fasting blood glucose level, animals
were fasted for 16 hr with free access to water. Blood glucose was moni-
tored at the end of each fasting period. Liver tissues were collected at the
end of experiments and immediately frozen in liquid nitrogen. Sections of
liver samples were fixed in 10% formaldehyde and analyzed under the fluo-
rescence microscope to determine infection efficiency. RNA was isolated
using Trizol solution (Invitrogen, Carlsbad, California), and liver RNAs, col-
lected from three mice within each experimental group, were pooled for
quantitative PCR analysis.
Glucose tolerance test
Mice were fasted for 16 hr prior to the glucose tolerance test and then
injected intraperitoneally with 2 g/kg body weight of glucose (Herzig et al.,CELL METABOLISM : NOVEMBER 2005
Role of TORC2 in insulin signaling2001; Koo et al., 2004). Blood glucose levels were measured from tail vein
blood collected at designated times.
Measurement of metabolites
Blood glucose levels were monitored from tail vein blood using an auto-
matic glucose monitor (One Touch, Lifescan, Fremont, California). Plasma
insulin levels were determined using a commercial insulin enzyme-linked
immunosorbent assay kit (Crystal Chem, Chicago, Illinois).
Quantitative PCR
Total RNA from either primary hepatocytes or liver tissue was extracted
using RNeasy mini-kit (Qiagen, Valencia, California). 500 ng (for primary
hepatocytes) or 1 g (for mouse liver) of total RNA was used for generating
cDNA with Superscript II enzyme (Invitrogen, Carlsbard, California). cDNAs
were analyzed by quantitative PCR using SYBR green PCR kit and an AB-
IPRISM 7700 Sequence detector (Perkin Elmer, Foster City, California). All
PCR data were normalized to ribosomal L32 expression in the correspond-
ing sample.
Western blotting
Whole cell protein was extracted from liver tissue in SDS-urea-lysis buffer.
50–100 g of protein was loaded onto a 6% SDS-polyacrylamide gel and
blotted onto nitrocellulose membrane (Schleicher & Schuell, Keene, New
Hampshire). Western blot assays were performed as described. Antisera
against IRS1 and IRS2 were from Upstate. Antibodies against Akt and GSK-
3β were purchased from Cell Signaling (Boston, Massachusetts).
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